Hyaluronic Acid Joint Pain Randomized Trial: What the Evidence Says

Quick Answer

Hyaluronic Acid Joint Pain Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 2 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• Recent meta-analyses have also underscored the limited evidence regarding the comparative effectiveness of pharmacological agents during this stage, reinforcing the importance of targeted investigations such as the present study. [CHANG Chih-Ya (2026); evidence level 2]
• As shown inand, the HA group exhibited a reduction in total SPADI score from 43.03 ± 17.65 at baseline to 16.14 ± 12.77 at week 26, while the rehabilitation group improved from 51.97 ± 18.35 to 23.21 ± 21.83. [CHANG Chih-Ya (2026); evidence level 2]
• Osteoarthritis (OA) is a degenerative disease characterized by the progressive degeneration of articular cartilage, the development of osteophytes, alterations in subchondral bone and synovial hyperplasia, clinically responsible for increasing disability and reduced quality of life. [Riglet Louis (2026); evidence level 2]
• In vitro studies also suggest improved stimulation of chondrogenesis, and a reduction in both inflammation and chondrocyte catabolism. [Riglet Louis (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is trial evidence in the current set, but population and intervention details still matter. For hyaluronic acid joint pain randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• CHANG Chih-Ya (2026). EFFICACY OF ULTRASOUND-GUIDED INTRA-ARTICULAR HYALURONIC ACID INJECTION IN THE MANAGEMENT OF ADHESIVE CAPSULITIS: A RANDOMIZED CONTROLLED TRIAL. DOI: 10.2340/jrm.v58.44901. PMCID: PMC13184811. PMID: 42136070. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13184811/
• Riglet Louis (2026). Efficacy and safety of a combination of platelet-rich plasma with non-crosslinked hyaluronic acid versus a crosslinked hyaluronic acid, in single-injection for knee osteoarthritis. Randomized, controlled, multicenter, non-inferiority trial. DOI: 10.1186/s12891-026-09625-z. PMCID: PMC13041446. PMID: 41735950. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ http://creativecommons.org/licenses/by-nc-nd/4.0/ This article is .... https://pmc.ncbi.nlm.nih.gov/articles/PMC13041446/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.